Methods for Engineering Allogeneic and Immunosuppressive Resistant T Cell for Immunotherapy

Cellectis

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 13 of these applications claim priority to application PCT/US2013/040766, filed May 13, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 10,342,829	Multi-Chain Chimeric Antigen Receptor and Uses Thereof Cellectis In force Term ends May 13, 2033 · Medium confidence	Cellectis	In force	Term ends May 13, 2033	Term ends May 13, 2033	Medium confidence
US 10,517,896	Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells Cellectis In force Term ends May 13, 2033 · Low confidence	Cellectis	In force	Term ends May 13, 2033	Term ends May 13, 2033	Low confidence
US 10,874,693	CD19 Specific Chimeric Antigen Receptor and Uses Thereof Cellectis In force Term ends May 13, 2033 · Medium confidence	Cellectis	In force	Term ends May 13, 2033	Term ends May 13, 2033	Medium confidence
US 11,007,224	CD19 Specific Chimeric Antigen Receptor and Uses Thereof Cellectis In force Term ends May 13, 2033 · Low confidence	Cellectis	In force	Term ends May 13, 2033	Term ends May 13, 2033	Low confidence
US 11,077,144	CD19 Specific Chimeric Antigen Receptor and Uses Thereof Cellectis In force Term ends May 13, 2033 · High confidence	Cellectis	In force	Term ends May 13, 2033	Term ends May 13, 2033	High confidence
US 11,274,316	Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells Cellectis In force Term ends May 13, 2033 · Low confidence	Cellectis	In force	Term ends May 13, 2033	Term ends May 13, 2033	Low confidence
US 11,304,975	Methods for Engineering Allogeneic and Highly Active T Cell for Immunotheraphy Cellectis In force Term ends May 13, 2033 · Low confidence	Cellectis	In force	Term ends May 13, 2033	Term ends May 13, 2033	Low confidence
US 11,311,575	Methods for Engineering Highly Active T Cell for Immunotheraphy Cellectis In force Term ends May 13, 2033 · Low confidence	Cellectis	In force	Term ends May 13, 2033	Term ends May 13, 2033	Low confidence
US 11,414,674	Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells Cellectis In force Term ends May 13, 2033 · Low confidence	Cellectis	In force	Term ends May 13, 2033	Term ends May 13, 2033	Low confidence
US 11,891,614	Methods for Engineering Allogeneic and Immunosuppressive Resistant T Cell for Immunotherapy Cellectis In force Term ends May 13, 2033 · Medium confidence	Cellectis	In force	Term ends May 13, 2033	Term ends May 13, 2033	Medium confidence
14 more patents in this group · Pro

10 of 24 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Pro members see all 24.

Upgrade to Pro

16 of these are in force and held by Cellectis.

Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.